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Abstract 
Review on GRM1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: GPRC1A, MGLU1, MGLUR1, 
SCAR13 




The mGluR1 gene contains 10 exons, which span a 
region of 409953 bp. 
Transcription 




GRM1 encodes five alternative splice variants (1a,  
1b, 1c, 1d, and 1e) (Zhu et al., 1999). All five 
variants contain the same N-terminal, but differ in 
the amino acid composition of their C-terminal 
domains due to the alternative splicings (DiRaddo 
et al., 2013). 
Description 
mGluR1 is an 1194 amino acid seven-
transmembrane domain G-protein coupled receptor 
normally expressed in neuronal and glial cells in the 
brain (Stephan et al., 1996; Hermans and Challiss, 
2001).  
Its natural ligand is the excitatory neurotransmitter, 
L-glutamate. Structurally, mGluR1 has various 
domains that are necessary for its functions.  
The N-terminus forms two large extracellular lobes 
separated by a cavity where the ligand glutamate 
binds to and is referred to as the amino terminal 
domain (ATD) or "Venus Fly Trap" (O'Hara et al., 
1993; Beqollari and Kammermeier, 2010).  
ATD is separated from the trans-membrane region 
of mGluR1 by a 70 amino acid cysteine rich 
domain (CRD), which is essential for dimerization, 
and activation of the receptor (Huang et al., 2011). 
The seven alpha-helical transmembrane domains 
(TMD) precede the cysteine rich region. 
 
Figure 1. Human GRM1 has 10 exons, which are depicted by boxes and shown with the relative position to one another. 
Adapted from DiRaddo et al., 2013. 
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Figure 2. There are five human mGluR1 isoforms. The black boxes represent the seven-transmembrane domains of mGluR1. 
Alternative splicing of mGluR1 mRNA produces five mGluR1 isoforms each with a unique C-termini, which is highlighted by the 
different colors. The shortest isoform, mGluR1e, is truncated before the seven-transmembrane domains, which results in the 
expression of only the amino terminal fragment (Costantino and Pellicciari, 1996). Adapted from Hermans and Challiss, 2001. 
 
 
Following the TMD is the carboxyl terminus of 
mGluR1, also known as the intracellular 
cytoplasmic tail domain (CTD). CTD is involved in 
modulating G-protein coupling and selectivity (Pin 
et al., 2003; Seebahn et al., 2013).  
The CTD is also the region subjected to alternative 
splicings, regulated by phosphorylation, and 
modulatory protein-protein interactions (Niswender 
and Conn, 2010).  
The CRD is consisted of three beta-pleated sheets 
and nine cysteine residues. CRD plays a key role in 
facilitating the allosteric coupling between the ATD 
and the TMD regions during ligand binding and 
receptor activation (Niswender and Conn, 2010). 
Upon activation of mGluR1 by glutamate, the 
signal induced is transmitted from the ATD through 
the CRDs, by way of a disulfide bridge formed 
between the 9th cysteine of the CRD and a cysteine 
residue in lobe 2 of the ATD (Rondard et al., 2006; 
Muto et al., 2007).  
As a result, a conformational change takes place 
that brings the C-terminal regions of the CRDs 
closer to one another and elicits cysteine-cysteine 
interaction in the e2 loop of the TMD (Muto et al., 
2007). This conformational change produces a shift 
in the TMD to induce G-protein activation (El 
Moustaine et al., 2012). 
Expression 
mGluR1 is normally expressed in the central  
nervous system and is activated by its natural 
ligand, L-glutamate (Teh and Chen, 2012a). Upon 
activation, mGluR1 couples to Gα/q11 proteins to 
induce phosphatidylinositol (4,5)-biphosphate 
(PIP2) hydrolysis leading to the formation of two-
second messengers, inositol 1,4,5-triphosphate 
(IP3) and diacyglycerol (DAG) (Conn and Pin, 
1997; Hermans and Challiss, 2001). These second 
messengers stimulate intracellular calcium release 
from the endoplasmic reticulum (ER) stores and 
activate protein kinase C (PKC), resulting in the 
stimulation of G-protein-independent signal 
transduction pathways (Hermans and Challiss, 
2001; Goudet et al., 2009).  
Such pathways include the mitogen activated 
protein kinase pathway (MAPK) and the 
phosphatidylinositol-3-kinase (PI3K)/AKT pathway 
(Marín, et al., 2006; Shin et al., 2010). 
Localisation 
Cell membrane of neurons. 
Function 
mGluR1 activation is involved in mediating 
neuronal excitability, synaptic plasticity, and 
feedback inhibition of neurotransmitter release 
(Speyer et al., 2012).  
All of which promotes learning and memory 
formation in the central nervous system (Hermans 
and Challiss, 2001). 
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Over 20 somatic missense mutations in the ligand 
binding and intracellular regulatory domains of 
mGluR1 have been identified in various tumors 
types (Sjöblom et al., 2006; Kan et al., 2010; 
Esseltine et al., 2013). A number of these mutations 
result in irregular mGluR1 stimulation of G protein 
coupling, biased ERK1/ERK2 phosphorylation, and 
intracellular retention in the endoplasmic reticulum 
(ER) (Esseltine et al., 2013). Such changes in 
mGluR1 signaling lead to abnormal receptor 




Melanoma is the most severe form of skin cancer 
and arises from the aberrant transformation of 
melanocytes. The most common mutations 
identified as drivers of melanomagenesis include B-
RAF and N-RAS activating mutations as well the 
tumor suppressors INK4a/ARF and PTEN (Teh and 
Chen, 2012a). 
Oncogenesis 
Glutamate signaling via mGluR1 has been shown to 
affect cell survival, cell differentiation and cell 
proliferation of non-neuronal tissues (Skerry and 
Genever, 2001; Shin et al., 2008). Chen and 
colleagues demonstrated the ectopic expression of 
mGluR1 in mouse melanocytes was sufficient to 
induce spontaneous metastatic melanoma 
development in transgenic mouse models, TG3 and 
Tg(Grm1)EPv (E) (Pollock et al., 2003). The 
ectopic expression of human mGluR1 was also 
detected in human melanoma cell lines and biopsy 
samples. To date, ~175 melanoma biopsy samples 
from primary to metastatic lesions have ben 
examined and found GRM1 mRNA and protein to 
be expressed in ~ 60% of the samples (Pollock et 
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al., 2003; Namkoong et al., 2007). Moreover, 
expression and activation of mGluR1 in melanoma 
cells has been shown to activate the MAPK and 
P13K/AKT pathways, two of the most frequently 
stimulated signaling cascades in melanoma (Marín 
et al., 2006; Shin et al., 2010). 
Breast cancer (triple-negative breast 
cancer) 
Disease 
Triple-negative breast cancer, are malignant tumors 
in breast tissue that lack estrogen receptor and 
progesterone receptor and amplification of the 
HER2 gene (Engebraaten et al., 2013). 
Oncogenesis 
Speyer and colleagues described mGluR1 
expression as a potential oncogene in mammary 
breast pathogenesis.  
They detected mGluR1 expression in multiple 
triple-negative breast cancer cell lines (TNBC) 
(Speyer et al., 2012). This group also provided 
evidences that the growth of TNBC cells was 
inhibited when mGluR1 expression was reduced by 
an shRNA or treatment with mGluR1 antagonist, 
Bay36-7620 (Speyer et al., 2012). 
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